English
Back
Open Account
HEARTCARE
wrote a column · Dec 29, 2021 12:48

Xinwei Comprehensive Solution has added two more major members! FullTrap Embolization Protector and Easywire Longchang Neurointerventional Microguide Wire were approved for sale in advance!

Xinwei Healthcare HEART CARE Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting lives and health. In five years, Xinwei Medical pioneered the only one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices. It has applied for more than 100 patents, has an annual production capacity of more than 150,000 pieces of products, and sales channels cover more than 1,000 hospitals in 29 provinces (including municipalities directly under the Central Government and autonomous regions). Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in China, and operating multiple emerging business segments including neurological intervention, electrophysiology, pulmonary intervention, and computer-assisted technology. It looks forward to continuously launching innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.
Xinwei Healthcare HEART CARE Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting lives and health. In five years, Xinwei Medical pioneered the only one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices. It has applied for more than 100 patents, has an annual production capacity of more than 150,000 pieces of products, and sales channels cover more than 1,000 hospitals in 29 provinces (including municipalities directly under the Central Government and autonomous regions). Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in China, and operating multiple emerging business segments including neurological intervention, electrophysiology, pulmonary intervention, and computer-assisted technology. It looks forward to continuously launching innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.
Xinwei Healthcare
HEART CARE
Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting lives and health. In five years, Xinwei Medical pioneered the only one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices. It has applied for more than 100 patents, has an annual production capacity of more than 150,000 pieces of products, and sales channels cover more than 1,000 hospitals in 29 provinces (including municipalities directly under the Central Government and autonomous regions). Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in China, and operating multiple emerging business segments including neurological intervention, electrophysiology, pulmonary intervention, and computer-assisted technology. It looks forward to continuously launching innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.
Xinwei Healthcare HEART CARE Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting lives and health. In five years, Xinwei Medical pioneered the only one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices. It has applied for more than 100 patents, has an annual production capacity of more than 150,000 pieces of products, and sales channels cover more than 1,000 hospitals in 29 provinces (including municipalities directly under the Central Government and autonomous regions). Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in China, and operating multiple emerging business segments including neurological intervention, electrophysiology, pulmonary intervention, and computer-assisted technology. It looks forward to continuously launching innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.
Xinwei Healthcare HEART CARE Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting lives and health. In five years, Xinwei Medical pioneered the only one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices. It has applied for more than 100 patents, has an annual production capacity of more than 150,000 pieces of products, and sales channels cover more than 1,000 hospitals in 29 provinces (including municipalities directly under the Central Government and autonomous regions). Based on its current leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in China, and operating multiple emerging business segments including neurological intervention, electrophysiology, pulmonary intervention, and computer-assisted technology. It looks forward to continuously launching innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient prognosis.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
2
38K Views
Report
Comments
Write a Comment...
2
3